CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 102 enrolled
Drug / intervention
Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav) +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00508469
NCT00508469Phase 4Completed
CompareCT.gov

Adherence of Patients Using Travalert® for Instillation of a Fixed Combination of Travoprost 0.004%/Timolol 0.5% Compared to a Concomitant Regimen of Travoprost 0.004% and Timolol 0.5%

Alcon Research·interventional·Posted Jul 30, 2007·Updated Jul 12, 2012

In Brief

A Phase 4 clinical trial evaluating Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav), Travoprost 0.004% eye drops, and 2 other interventions for Open-angle Glaucoma and Ocular Hypertension. Completed, enrolled 102 participants across 1 site.

Detailed Summary

The purpose of the study is to compare adherence in patients on a fixed combination of travoprost 0.004%/timolol 0.5% and patients on a concomitant combination of travoprost 0.004% and timolol 0.5% using the Travalert® device.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen-angle Glaucoma, Ocular Hypertension
CountriesSpain
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 30, 2007
Enrollment StartOct 1, 2007
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.9 years ago

Interventions

Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav)drug

One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.

Travoprost 0.004% eye dropsdrug

One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.

Timolol 0.05% eye dropsdrug

One drop in the study eye twice daily at 9 a.m. and 9 p.m. for six months using the Travalert device.

Travalert Dosing Aiddevice

Approved device used with study medication to record time of instillation and quantify dosing